Ligand’s Third Quarter Financial Results to be Reported October 30th 2020/10/19 20:02:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call. Third Quarter 2020 Earnings Conference Call What: Ligand conference call to discuss financial results and provide general business updates Date: Friday, October 30, 2
Ligand to Divest Vernalis Research Operations 2020/10/12 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the terms of the agreement, Ligand will retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships. The tra
Ligand: The Small Cap Powering Gilead's Remdesivir 2020/10/05 21:47:37 Benzinga
President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: REGN ) and remdesivir, an antiviral treatment from Gilead Sciences (NASDAQ: GILD ). About Remdesivir: The FDA approved remdesivir for emergency use in May. Remdesivir was shown to shorten the recovery time for patients in the hospital with COVID-19. In June, Gilead announced the pricing of remdesivir: $390 per vial. The average five day treatment uses six vials, which would cost $2,340. Gilead has shown that the treatment can shorten the hospital stay of patients by four days, or $12,000 in hospital costs. On Monday, Trump announced he was leaving Walter Reed Hospital. later in the day. The doctors said Trump received three treatments of remdesivir and would receive a fourth before leaving the hospital. A fifth treatment of remdesivir will be given at the White House. Captisol The Key Ingredient: Captisol, which is owned by Ligand Pharmaceuticals (NASDAQ: LGND ), is a chemical structure that makes products soluble.
Ligand to Host Virtual Investor Day on October 20th 2020/10/02 12:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt Foehr, President and Chief Operation Officer Matt Korenberg, Chief Financial Officer Vince Antle, PhD, SVP Technical Operations and Quality Assurance Patrick Lucy, SVP and Chief Business Officer, Protein
Ligand Closes $438M Pfenex Deal; Street Sees 84% Upside 2020/10/02 06:30:02 Smarter Analyst
Ligand Pharmaceuticals announced that it has completed the acquisition of Pfenex Inc. for $437. The post Ligand Closes $438M Pfenex Deal; Street Sees 84% Upside appeared first on Smarter Analyst .
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma 2020/08/24 12:30:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd) in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who
PFENEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pfenex Inc. - PFNX 2020/08/15 00:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pfenex Inc. (NYSE: PFNX) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of Pfenex will receive $12.00 in cash, and a one-time contingent value right of $2.00 in the event a predefined regulatory milestone is achieved by December 31, 2021, for
Ligand Pharmaceuticals to acquire fellow San Diego biotech Pfenex for up to $516M 2020/08/11 18:45:10 San Diego Union-Tribune
Ligand Pharmaceuticals is set to acquire Pfenex in the fourth quarter of 2020. The two San Diego biotechs rely on developing early-stage tools and licensing them out to other companies.
CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application 2020/08/07 12:30:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based chemotherapy met its pre-specified primary endpoint, as assessed by the independent Data Monitoring Committee at the planned interim analysis of CS1001-302, a randomized, double-blind Phase 3 clinical trial for the first-line treatment of stage IV squamous and non-squamo
Ligand Reports Second Quarter 2020 Financial Results 2020/08/03 11:30:00 Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an
Ligand Pharmaceuticals Incorporated : CEO Issues Letter to Captisol Customers | MarketScreener 2020/06/01 20:54:02 MarketScreener
Ligand Pharmaceuticals Incorporated announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows: To… | June 1, 2020
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases 2020/05/29 12:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new program incorporates Icagen’s ion channel technology and expertise and is directed at a specific novel ion channel target relevant to neurodegenerative di
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics 2020/05/28 20:22:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors. The milestone payment will consist of $2 million in cash and $1 million in Palvella Series C Preferred Stock. Palvella is a privately-held rare disease biopharmaceutical company focused on develop
Should Value Investors Buy Ligand Pharmaceuticals (LGND) Stock? 2020/05/14 15:50:14 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ligand Pharmaceuticals (LGND) Q1 Earnings and Revenues Beat Estimates 2020/05/06 21:45:06 Zacks Investment Research
Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?